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Background: Gradual ascent to high altitude is typically associated with reduced resting aldosterone 
and unchanged cortisol, features that may facilitate acclimatization but are poorly understood.  
Aims: To investigate the cortisol and aldosterone response to adrenocorticotrophic hormone at 
altitude. 
Methods: Eleven subjects underwent a 250 µg short synacthen test at sea-level and again after 
trekking to 3600 m in Nepal. Cortisol and aldosterone were measured by conventional assay from 
blood samples taken immediately prior to the administration of synacthen (T0) and then 30 (T30) 
and 60 (T60) minutes later.   
Results: At 3600 m resting basal cortisol and aldosterone levels were both significantly lower than 
they were at sea-level (p=0.004, p=0.003 respectively). Cortisol values at T30 and T60 were no 
different between sea-level and 3600 m but the increment after synacthen was significantly 
(p=0.041) greater at 3600 m due to a lower basal value. Aldosterone at T30 and T60 was significantly 
lower (p=0.003 for both) at 3600 m than at sea-level and the increment following synacthen was 
also significantly (p=0.003) less at 3600 m.    
Conclusions: At 3600 m there appears to be a divergent adrenal response to synthetic 
adrenocorticotrophic hormone with an intact cortisol response but a  reduced aldosterone response, 
relative to sea-level. This may reflect a specific effect of hypoxia on aldosterone synthesis and may 
be beneficial to acclimatization. 





The adrenocortical hormones aldosterone and cortisol contribute to fluid and sodium retention via 
their action on mineralocorticoid receptors in the renal nephron. Acclimatization to high altitude 
(HA) is associated with a natriuresis and a diuresis [1]. With gradual ascent to HA resting cortisol 
levels typically remain unchanged [2-7] and have been noted to decrease [8]. Our own data [2] have 
shown no change until subjects are nearing extreme altitude where a rise in resting morning cortisol 
was noted at 5150 m. Conversely, in studies in which subjects are rapidly exposed to hypoxic 
conditions, either in a hypoxic chamber or using a vehicle to ascend rapidly cortisol has been noted 
to increase [9-16]. Cortisol levels at HA have been shown to correlate with fluid retention [17] and 
the severity of acute mountain sickness (AMS) [9, 13]. Gradual rather than rapid ascent, at least 
beneath altitudes of 5000 m, may therefore prevent a rise in cortisol that could otherwise contribute 
to the fluid retention which is associated with AMS [1, 18, 19]. 
Resting adrenocorticotrophic hormone (ACTH) levels are elevated on acute exposure to hypobaric 
hypoxia equivalent to 3000 m without any difference in resting cortisol levels [3].  Sixty minutes of 
exercise in the same hypoxic conditions was also noted to produce an equivalent rise in ACTH to that 
seen in normoxia but with a blunted cortisol response. Together these findings suggest altered 
adrenal sensitivity to ACTH under hypoxic conditions. Post-mortem studies in high-altitude natives 
(HANs) have also suggested greater pituitary corticotroph numbers than in sea-level (SL) natives, 
along with physiological adrenal hyperplasia [20] again hinting at an altered relationship between 
ACTH and cortisol at HA. In support of this hypothesis it must be noted that the administration of 
corticotrophin releasing hormone to HANs at moderate altitude has been shown to induce a rise in 
ACTH but no subsequent increase in cortisol [21] and that HANs also demonstrate a subdued cortisol 
response to ACTH [22].  
Most reports from both hypoxic chamber studies [9, 23, 24] and field studies [4, 7, 8, 25, 26], show a 
reduction in resting aldosterone at HA which is likely to be beneficial since it would facilitate a 
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diuresis and a natriuresis. These findings are supported by in vitro studies, which have found that 
aldosterone production by adrenocortical cells in response to ACTH is significantly reduced in 
hypoxic conditions [27]. However, not all studies have reported a reduction in aldosterone upon 
ascent to HA and several which have reported a rise have found that the increase correlated closely 
with ACTH levels [10, 28, 29]. High levels of aldosterone at HA are associated with marked increases 
in total body water and plasma volume [30] and have been shown to correlate with the severity of 
AMS [28]. 
There are significant gaps in the literature regarding the adrenal response to HA. The cortisol 
response to ACTH has only been assessed following acute hypoxia or rapid ascent  [7] and the 
aldosterone response to ACTH similarly has only been assessed following acute hypoxia and 
dexamethasone [31]. As we have discussed the rate of ascent can markedly affect the adrenal 
response to altitude. In reality most people ascending to altitude will do so by following a recognised 
trekking profile.  Therefore, the most appropriate way to investigate any change in the adrenal 
response to HA is to do so during a typical trek. We therefore aimed to assess cortisol and 
aldosterone levels at rest at SL and following a typical trek to HA. Cortisol is primarily under the 
control of ACTH and while aldosterone is predominantly under the control of the RAS it does 
demonstrate a response to ACTH -[32] We therefore also aimed to assess the adrenal response 
following stimulation with synthetic ACTH (synacthen) at SL and HA.      
Materials and methods: 
Ethical approval 
Ethical approval (protocol  579/MODREC/14) was granted by the Ministry of Defence Research 
Ethics Committee, Whitehall, UK, and research was conducted in accordance with the Declaration of 
Helsinki. All subjects gave written, informed consent before testing and an independent medical 
officer was present at all times.  
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Subjects and ascent profile 
Twelve serving UK military personnel (9 male, 3 female) who were taking part in an expedition to the 
Dhaulagiri Circuit in Western Nepal were recruited to take part in the study. None of the participants 
had been exposed to HA in the 6 months prior to the study, had a significant history of any HA 
illnesses or took any medication to aid acclimatisation. Exclusion criteria included any significant 
medical condition or the taking of any medication that may affect cortisol or aldosterone (such as 
anti-hypertensives).  Participants flew from SL in the UK to Kathmandu (1300 m) and reached Italian 
Base Camp (3600 m) on Dhaulagiri I’s West face by foot 10 days later after following a gradual ascent 
profile.  
AMS scores and basic physiological observations 
Scores of AMS and measures of resting systolic and diastolic blood pressure (SBP, DBP), heart rate 
(HR), respiratory rate (RR) and oxygen saturation (SpO2) were recorded every morning and evening 
during the expedition until participants started to descend on day 12. Participants recorded their 
own AMS scores using the Lake Louise Score (LLS) questionnaire [33]. BP was recorded using an 
Omron M6 automatic BP monitor (Omron Healthcare, UK). SpO2 and HR were recorded using a 
Nellcor NP-20 handheld pulse oximeter (Covidian, MA, USA). RR was recorded manually by observing 
chest rise and fall.  
Short synacthen test (SST) 
Baseline testing was performed in the UK at SL (220 m or 350 m) one month prior to the beginning 
of the expedition. HA testing was performed at 3600 m, 48 hours after arriving at that altitude. A 20 
G cannula was inserted in to the ante-cubital fossa of participants and basal (T0) samples of 4 ml 
venous blood were drawn into one serum separation tube vacutainer and one EDTA vacutainer. 250 
µg synacthen was then administered through the cannula and flushed. Further 4 ml venous blood 
samples were collected through the cannula at 30 minutes (T30) and 60 minutes (T60) post-
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synacthen administration. Both SL and HA SST were performed at the same time of day (09:30) on 
well-rested subjects who had eaten a light breakfast 1 hour previously. Fluid intake during the 
expedition was not restricted or monitored but participants refrained from caffeine during the 
mornings before testing. During testing participants remained at rest in a seated position and 
refrained from eating or drinking. HA testing was performed in a tent where the ambient 
temperature was 17°C.  
Laboratory analysis 
Blood samples were immediately centrifuged and the serum and plasma stored in cryovials that 
were frozen at minus 20°C. One unintended freeze-thaw cycle occurred due to interruption of the 
power supply while on the mountain.  Samples were analysed in the Clinical Biochemistry 
department, Royal Victoria Infirmary, Newcastle upon Tyne, UK. Serum sodium, potassium, urea, 
creatinine and osmolality were assayed by conventional means on baseline samples from SL and 
3600 m. Cortisol assays were performed using the Roche Elecsys Cortisol I assay on serum samples. 
The test is a competitive chemiluminescence immunoassay (CLIA) and is fully automated, run on the 
Roche modular E unit (Roche Diagnostics, Burgess Hill, UK).  The analytical range of the assay is 0.5 –
1750 nmol/L. Low levels are reported as “<20 nmol/L”. The lower detection limit of 0.5 nmol/L 
represents the lowest measurable analyte level that can be distinguished from 0. There is an intra-
assay coefficient of variation (CV) of 9.3-11.7%. The functional sensitivity of the assay is <8.5 nmol/L. 
Aldosterone assays were performed using the IDS iSYS assay on plasma samples collected using 
EDTA vacutainers. The assay is a CLIA and is fully automated, run on the IDS iSYS immunoassay 
analyser (IDS PLC, Boldon, UK). It has an analytical range of 103-3656 pmol/L with low levels being 
reported as “<103 pmol/L”. The lower limit of quantification represents the lowest concentration of 
analyte that can be measured with acceptable precision. There is an intra-assay CV of 5.8-12.1%.   
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Following the expedition an investigation into the effect of an additional freeze-thaw cycle on 
aldosterone values was undertaken using 33 anonymised patient samples that had been submitted 
for routine aldosterone measurement. 
Statistical analysis 
Statistical analysis of the results was performed using SPSS 18.0 software. Data were examined for 
normal distribution using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Normally distributed data 
are described using the mean and standard deviation (SD) whilst non-normally distributed data are 
described using the median and range. Comparisons of normally distributed paired data were done 
using the paired t-test. When one or both sets of paired data were not normally distributed 
comparisons were made using the Wilcoxon Signed Ranks test. Pearson’s correlation coefficient or 
Spearman’s correlation coefficient were calculated according to data distribution. A p-value of <0.05 
was considered to be significant. Data for males and females were analysed together as there was 
no significant difference between sexes.   
Results: 
Medical screening revealed that one participant had a history of nephrectomy for chronic 
pyelonephritis with secondary hypertension and their data were excluded.  The remaining 9 male 
and 2 female subjects were 25.9±2.5 years old, weighed 73.2±7.8 kg and were 172.6±5.4 cm tall with 
a body mass index of 24.5±1.5 kg/m2. 
SpO2 (%) was significantly lower (p<0.0005) at 3600 m than it was at 1300 m (92.2±2.2 vs 98.01.0). 
Between SL and 3600 basal serum sodium (140.3±2 vs 141±2, mmol/l, p=0.2); creatine (88.3±13 vs 
89.2±14, umol/l, p=0.9) and osmolality (282.9±2.8 vs 281.8±2.5, mosmol/kg, p=0.3)  did not change. 
Between SL and 3600 m basal potassium rose significantly (4.37±0.2 vs 4.62±0.3, mmol/l, p=0.04) 
and urea fell significantly (5.33±1 vs 3.1±1, mmol/l, p<0.01). 
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The change in cortisol with SST is shown in Figure 1. The increase in cortisol from T0-T30, T0-T60 and 
T30-T60 was significant at both SL and 3600 m (p<0.0005). Basal (T0) cortisol (nmol/l) was 
significantly lower (p=0.004) at 3600 m than at SL (373.6±59.8 vs 477.6±97.9). Cortisol at T30 and 
T60 was not significantly different at 3600 m compared to SL. The increase in cortisol [nmol/l, 
median (range)] from T0-T30 was significantly greater (Z=-2.491, p=0.013) at 3600 m than at SL 
[410(319-489) vs 312(221-564)] and the increase in cortisol from T0-T60 was also significantly 
greater (p=0.041) at 3600 m than at SL [572(492-655) vs 482(395-765)].  
At 3600 m the concentration of aldosterone in 18/33 samples fell below the lower limit of 
quantification of the assay (103 pmol/L). These results were assigned a value of 103 pmol/L to allow 
for statistical analysis and graphical representation. Aldosterone values following SST at SL and 3600 
m are presented in Figure 2. Following the administration of synacthen at SL there was a significant 
increase in aldosterone from T0-30 and T0-60 (Z=-2.934, p=0.003 for both tests). Basal (T0) 
aldosterone [pmol/L, median (range)] was significantly lower (Z=-2.934, p=0.003) at 3600 m than at 
SL [103(103-142) vs 234(167-520)]. Aldosterone at T30 and T60 was also significantly lower (Z=-
2.934, p=0.003 for both tests) at 3600 m than at SL [138(103-448) vs 806(366-1833) and 120(103-
389) vs 755(420-1753)]. The increase in aldosterone [pmol/L, median (range)] from T0-T30 was 
significantly lower (Z=-2.934, p=0.003) at 3600 m than at SL [35(0-306) vs 517(199-1313)]. The 
increase in aldosterone from T0-60 was also significantly lower (Z=-2.934, p=0.003) at 3600 m than 
at SL [17(0-247) vs 520(253-1233)].  
Investigation of the effect of an additional freeze-thaw cycle on values of aldosterone assayed after 
an additional freeze-thaw cycle showed excellent correlation with a linearity of y=0.9748x+3.8211.  
At 3600 m basal cortisol inversely correlated with SpO2 (rp=-0.658, p=0.028) and the increase in 
cortisol from T0-T30 positively correlated with SpO2 (rs=0.758, p=0.007) as did the increase in cortisol 
from T0-T60 (rs=0.817, p=0.002).   
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None of the AMS scores recorded by subjects using the LLS were above the threshold for diagnosing 
AMS on any occasion during the expedition. 
Discussion  
To our knowledge this is the first study to report the adrenal response to synthetic ACTH at HA 
following a gradual ascent by means of trekking. We have demonstrated that while the adrenal 
response to ACTH in terms of cortisol remains intact the aldosterone response is subdued. We also 
demonstrated, in line with previous reports, a fall in resting aldosterone at HA and a less frequently 
reported fall in resting cortisol.  
Adrenocortical sensitivity to ACTH at HA has only been previously evaluated under acute hypoxic 
conditions or following rapid vehicular ascent. As discussed in the introduction the rate of ascent has 
a significant influence on the cortisol response to HA and our data more closely reflects the effect of 
the real-world scenario of trekking.   
Our data regarding cortisol are consistent with a report from 1982 [7] concerning three subjects that 
showed no difference in plasma cortisol or 24 hour urine free cortisol in response to synacthen (250 
µg IM) between SL and 3 days after being driven for 5 hours to 4350 m. Similarly, it was reported in 
1966 [34] that 12 subjects taken by train (10.5 hours) from SL to 4350 m demonstrated an intact 
adrenal response (as assessed by 24-hour urine measurements of 17-ketosteroids) to two injections 
of intramuscular ACTH (80 units) given 12 hours apart.  
Our findings regarding a subdued aldosterone response to ACTH are also in line with a study [31] 
that administered low-dose synacthen (0.125 µg, 0.25 µg, 0.5 µg and 1.25 µg) following 
dexamethasone at SL in normoxia and then while breathing a hypoxic gas mixture designed to 
reduce SpO2 to 90%. The authors of this study reported  a significant reduction in the aldosterone 
response to ACTH under the hypoxic conditions with an intact cortisol response.  
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It is interesting to note that in rats severe hypoxia specifically inhibits (in vitro) adrenal aldosterone 
synthesis and aldosterone synthase mRNA without a change in other mitochondrial cytochrome P-
450 enzyme activities with a reduction in corticosterone conversion to aldosterone [35].  In addition, 
in vitro bovine adrenocortical cells exposed to hypoxia demonstrate a selective reduction in ACTH-
stimulated aldosterone production while maintaining an intact cortisol response [27]. Taken 
together these in vitro data offer a plausible explanation as to why we found an intact cortisol 
response but a subdued aldosterone response to ACTH in humans at HA. 
The finding that basal cortisol was significantly lower at 3600 m than at SL supports the hypothesis 
that following a gradual ascent, cortisol levels are lower at HA than they are at SL. It is also 
consistent with the findings of McLean et al. [8] who reported a significant drop in basal cortisol as 
high as 4500 m. The results are contrary to the findings of several other papers which have reported 
an increase in cortisol upon rapid ascent to HA in both field [12-16] and chamber studies [9-11] and 
probably reflect that the adrenal cortisol response to hypoxaemia is highly dependent on the rate of 
ascent. It is highly unlikely that any fluctuation in cortisol at the altitude we used would significantly 
affect aldosterone levels since even high doses of prednisolone demonstrate no effect on basal 
aldosterone [36] 
The finding that basal aldosterone was significantly lower at HA supports the hypothesis that, 
following a gradual ascent to HA, plasma levels of the hormone are lower than they are at SL. These 
findings concur with the bulk of HA field studies [4, 7, 8, 25, 26] though this is not a universal finding 
[24, 37, 38]. Aldosterone release may be inhibited by a fall in potassium or an increase in blood 
volume but our findings that basal potassium rose slightly while osmolality did not change would be 
against these factors having an influence at HA.  
While the numbers are too small to rely on correlation analysis it is interesting to note the inverse 
correlation between SpO2 and basal cortisol at 3600 m.  It is possible that this may relate to 
sympathetic interaction with the hypothalamic-pituitary-adrenal axis due to hypoxia whilst the 
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positive correlation between SpO2 and the rise in cortisol post-synacthen may reflect those with a 
higher SpO2 having lower basal cortisol levels and an intact adrenocortical reserve. 
In conclusion, following a gradual ascent to 3600 m, we found both cortisol and aldosterone levels to 
be lower than at SL. The response to SST suggests that while the cortisol response to ACTH remains 
intact at altitude the aldosterone response appears to be subdued. This raises the possibility that 
hypoxaemia is capable of selectively inhibiting ACTH-stimulated aldosterone secretion in humans.  
This may reflect a beneficial response to HA that facilitates acclimatization and reduces the risk of 
fluid retention. 
We can only speculate on potential mechanisms for our current observations and further 
investigation is warranted. Future studies could interrogate the effects of HA on adrenal function 
further by incorporating assay of cortisol and aldosterone precursors as well as aspects of the RAS 
such as angiotensin II. In addition, investigation of other adrenal hormones that are under ACTH 
control, such as androstenedione and DHEAS would provide further useful information. Finally, more 
potent stimulation of adrenal aldosterone secretion could be obtained using infusion of angiotensin 
II. 
Limitations 
We acknowledge that this study has several limitations. Basal ACTH levels were not measured so it is 
not known whether the low basal cortisol and aldosterone levels measured at 3600 m are a product 
of low ACTH levels, adrenocortical blunting to ACTH or a combination of both.  While we 
acknowledge that cortisol is primarily under the control of ACTH and aldosterone under the RAS [32] 
we still have clearly shown that synacthen induces a significant rise in aldosterone at SL and that this 
is significantly blunted at HA, unlike the cortisol response to synacthen. 
We had originally intended to perform SST at additional altitudes of 4200 m and 5000 m but due to 
severe snowfall it was unsafe for the team to ascend higher. Partly as a result of severe weather 
12 
 
conditions it became a challenge to maintain power to the freezer from the generator. While it is 
clearly desirable to avoid unnecessary freeze-thaw cycles in any assay we sustained an un-intended 
freeze-thaw cycle while in Nepal. On return to the UK we performed aldosterone assays on a patient 
cohort of 33 subjects following an additional freeze-thaw cycle and obtained reassuring results 
regarding the stability of aldosterone under such circumstances. This is supported by data showing 
that, having subjected aldosterone samples to two and three freeze-thaw cycles, values were still 
within 96.8-105.2% of the original [39]. Other workers have also reported that three freeze-thaw 
cycles have very little effect on the concentrations recorded of multiple hormones [40] and in one 
extreme, following 10 freeze-thaw cycles, aldosterone was only found to drop by 6.2% [41]. As best 
we can, therefore, we feel our data are a true reflection on the effect of HA. 
Finally, while we did perform SST at SL we did not perform SST at SL after a ten-day trek at SL. While 
we therefore cannot fully exclude a confounder of exercise on our results we think any effect would 
be minimal since the subjects were well rested for 48 hours at 3600 m before SST was performed.  
Legends of tables and figures: 
Figure 1: Bar chart of mean plasma cortisol at SL and 3600 m clustered by time (0 min (basal), 30 
mins or 60 mins) during the SST. 
Figure 2: Bar chart of mean plasma aldosterone at SL and 3600 m clustered by time (0 min (basal), 
30 mins or 60 mins) during the SST. 
Figure 3: Correlation between serum aldosterone measured before and after an additional freeze-
thaw cycle for 33 patient samples. Passing-Bablok regression line shown (y=1.066x + 8.0).  
Figure 4: Difference plot for serum aldosterone measured before and after an additional freeze-
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